



TABLE OF CONTENTS



About	02
The year in review	03
Financial Information	05
Financial Statements	06

ABOUT

MISSION

To promote health by leading the fight against Dupuytren's disease (DD) in Canada by helping people with DD live a healthy and functional life while we work to find a cure.

To promote health by finding the best available care and treatment for people suffering from DD and the related Ledderhose disease (LD). To advance education related to DD by providing latest services and educational material to the public.

To promote health by encouraging the search for the underlying causes and subsequent cures for DD and LD.

GOALS

- Expanding the CDS website
- Funding of research on the prevalence of DD
- Clinical information exchange




THE YEAR IN REVIEW

The year 2023 was a year of technological adaptation following the upgrade of the Society's website. One priority was to add content that had been delayed by the migration.

The discontinuation of Xiaflex injections for the treatment of Dupuytren's disease led to a decline in the number of surgeons offering this option. This resulted in an outdated list of doctors who were no longer able to provide treatment, which had to be updated. Significant time has been invested in cleaning up the list and it is now well advanced.





THE YEAR IN REVIEW - CONTINUED



QUESTIONNAIRE AND PATIENT'S SURVEY

The Society undertook to translate and test the Mymop Symptom Self-Assessment Questionnaire to assess patients' symptoms in order to collect information through the website. This exercise revealed that the questionnaire was not ideal for the intended audience and means of use. The Society therefore focused on developing a customized questionnaire to assess how patients in Canada manage their disease, the key issues and challenges they face, and the support needs they would like the Society to address.

JOINT INNOVATION GRANT WITH THE ARTHRITIS SOCIETY

The joint Arthritis Society of Canada/Canadian Dupuytren Society Stimulating Research grant program saw no research projects requiring the grant in 2023, and the Society has decided to continue its participation to the program for 2024.

ONLINE INFORMATION REQUESTS

In the last 12 months, the Society has experienced a steady stream of online requests for information on Dupuytren's disease and related conditions, with a total of almost 250 requests answered.

Most patients are looking for specialists in their area and/or want to know about potential treatments. Many are looking for collagenase injections (Xiaflex - which is no longer available in Canada as of June 2020) and others are wondering whether certain injections (corticosteroids, Hyaluronidase, Verapamil, Adalimumab, etc...) are recommended. A few patients would like to take part in a clinical trial. To better respond to these requests for information, the Society will need to continue to develop content on treatments, and to find more specialists who treat Dupuytren's disease in each province. The database of specialists, which was updated in 2024, includes over 80 specialists, of whom only 15 are radio oncologists.

PRIVACY AND CONFLICT OF INTEREST POLICIES

A privacy commissioner for the information the CDS collects has been appointed, and a policy is being finalized to comply with Canadian and various provincial regulations.

FINANCIAL INFORMATION

ANNUAL RESULTS

The Canadian Dupuytren Society ("CDS") financial position at year end remains strong with cash reserves exceeding \$44,000. For the year ended December 31, 2023, total revenues generated amounted to more than \$18,000 and expenditures amounted to approximately \$6,800. The majority of expenditures, totaling \$3,474 related to the continued development and maintenance of the CDS website. The final website development costs incurred in 2023 came in lower than budgeted and the website is now substantially complete.

Operational costs for general and administrative incurred in the year remain low and totaled approximately \$3,200.



+ 18 000 \$



FORECASTS



For 2024, we are budgeting \$14,000 of revenue and are projected to incur approximately \$21,750 in expenditures. The majority of our budgeted expenditures, approximately \$20,050, will be incurred and relate to our charitable program costs.

FINANCIAL STATEMENTS

PLEASE FIND BELOW THE FINANCIAL STATEMENTS FOR THE YEAR ENDING DECEMBER 31, 2023.

Financial Statements of

Canadian Dupuytren Society

As of December 31st, 2023 and for the year ended December 31st, 2023

Société canadienne de Dupuytren

Statements of Financial Position

December 31		ecember 31,	December 31, 2022	
Assets	202	2023		
Current Assets				
Cash	\$	44 765.74	\$	32 731é75
Accounts Receivable		60.00		190.42
GST/QST ITCs		2 479.95		3 138.59
Total Assets	\$	47 305.69	\$	36 060.76
Liabilities & Equity				
Liabilities	φ.	721 20	Φ.	720.00
Accounts Payable	\$	731.30	\$	720.00
Equity	\$	46 574.39	\$	35 340.76
Total Liabilites & Equity	\$	47 305,69	\$	36 060,76

Approved by the Board of Directors of the Canadian Dupuytren Society:					
Director: Paule Gauthier	Director: Bruce Pachkowski				

80

Canadian Dupuytren Society

Statements of Operations

December 31, 2023		31 décembre 2022		
Revenue				
Donations	\$	17 841.36	\$	17 127.24
Membership Fees		160.00		120.00
	\$	18 001.36	\$	17 247.24
Operating Expenditures				
National Communication & Public Awareness Expenditure	\$	3 473.74	\$	18 571.14
Insurance		795.80		845.80
Business Lincences & Membership		885.30		872.00
Donation Expenses & Bank Charges		644.98		570.90
Administration and Processing		847.91		2 976.69
Office Supplies		120.00		0.00
	\$	6 767.73	\$	23 836.53
Excess (Deficit) of Revenue over Expenditures	\$	11 233.63	\$	(6 589.29)





HAVE ANY QUESTIONS? GET IN TOUCH WITH US!

www.dupuytrencanada.ca info@dupuytrencanada.ca